Study S001225

An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01940965
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 294
Start: 2013-09
Primary completion: 2015-07
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:lixisenatide AVE0010; DRUG:biguanide; DRUG:TZD; DRUG:alpha-GI; DRUG:glinide
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1129-8754

Registered primary outcomes

Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data [52 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024986	Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study. Seino Y, Journal of diabetes investigation	2018	Other trial	PMID 28429860 DOI	cites ClinicalTrials.gov:NCT01940965